Related Experiment Video
Updated: Nov 5, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer
David E Heppner1,2, Michael J Eck3,4
1Department of Chemistry, University at Buffalo, State University of New York, Buffalo, New York, USA.
Precision oncology targets cancer-driving proteins. Structural biology advances inhibitor discovery for key signaling pathways like EGFR and RAS, opening new avenues for targeted cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Precision oncology aims to inhibit proteins driving cancer growth.
- The receptor tyrosine kinase-RAS-MAPK pathway is frequently mutated in cancers.
- Key proteins like EGFR, SHP2, RAS, BRAF, and MEK are critical targets.
Purpose of the Study:
- To review historical and recent efforts in developing inhibitors for cancer signaling pathways.
- To emphasize the role of structural biology in inhibitor discovery and characterization.
- To explore how structural insights reveal new vulnerabilities for drug development.
Main Methods:
- Review of literature on targeted cancer therapies.
- Analysis of structure-based drug design approaches.
- Examination of structural biology findings on protein regulation and mutations.
Main Results:
- Significant progress has been made in developing inhibitors for the RAS-MAPK pathway.
- Structural biology has been crucial for understanding inhibitor mechanisms and optimizing drug design.
- New therapeutic strategies are emerging based on allosteric regulation and oncogenic mutation effects.
Conclusions:
- Understanding protein structure and regulation is vital for advancing precision oncology.
- Structural biology provides critical insights for discovering and characterizing novel cancer drugs.
- Targeting key signaling nodes offers promising avenues for effective cancer treatment.
More Related Videos
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Receptor Tyrosine Kinases
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...